| Identification | Back Directory | [Name]
NFκB Inhibitor | [CAS]
213546-53-3 | [Synonyms]
SN50
NFkB Inhibitor
NF-KAPPA-B SN50
NF-κB Inhibitor, SN50
NF-KAPPAB INHIBITOR SN50
AAVALLPAVLLALLAPVQRKRQKLMP
NF-κB Inhibitor, SN50, >=97%
NUCLEAR FACTOR NF-B INHIBITOR SN50
NUCLEAR FACTOR NF-KAPPA-B INHIBITOR SN50
NF-KAPPA-B SN50, CELL-PERMEABLE INHIBITOR PEPTIDE
NF-KAPPAB SN50, CELL-PERMEABLE INHIBITORY PEPTIDE
FGF-4 PRECURSOR (7-22) (HUMAN)-EBP-1 (359-368) (HUMAN)
HST-1 PRECURSOR (7-22) (HUMAN)-DNA-BINDING FACTOR KBF1 (359-368) (HUMAN)
FIBROBLAST GROWTH FACTOR-4 PRECURSOR (7-22) (HUMAN)-NUCLEAR FACTOR NF-KAPPA-B P105 SUBUNIT (359-368) (HUMAN)
H-ALA-ALA-VAL-ALA-LEU-LEU-PRO-ALA-VAL-LEU-LEU-ALA-LEU-LEU-ALA-PRO-VAL-GLN-ARG-LYS-ARG-GLN-LYS-LEU-MET-PRO-OH
FGF-4 Precursor (7-22) (huMan)-EBP-1 (359-368) (huMan), HST-1 Precursor (7-22) (huMan)-DNA-Binding Factor KBF1 (359-368) (huMan), Fibroblast Growth Factor-4 Precursor (7-22) (huMan)-Nuclear Factor NF-ΚB p105 Subunit (359-368) (huMan) TFA
L-Proline, L-alanyl-L-alanyl-L-valyl-L-alanyl-L-leucyl-L-leucyl-L-prolyl-L-alanyl-L-valyl-L-leucyl-L-leucyl-L-alanyl-L-leucyl-L-leucyl-L-alanyl-L-prolyl-L-valyl-L-glutaminyl-L-arginyl-L-lysyl-L-arginyl-L-glutaminyl-L-lysyl-L-leucyl-L-methionyl- | [Molecular Formula]
C129H230N36O29S | [MDL Number]
MFCD01076531 | [MOL File]
213546-53-3.mol | [Molecular Weight]
2781.5 |
| Chemical Properties | Back Directory | [density ]
1.36±0.1 g/cm3(Predicted) | [storage temp. ]
-20°C | [form ]
film | [color ]
colorless | [Water Solubility ]
Water : ≥ 50 mg/mL (17.98 mM) |
| Hazard Information | Back Directory | [Uses]
NFkappaB Inhibitor is inhibits translocation of the NFκB active complex into the nucleus. | [Biochem/physiol Actions]
SN50 is an NF-κB cell permeable inhibitory peptide. The SN50 sequence contains the nuclear localization sequence (NLS residues 360-369) of the transcription factor NFκB p50 linked to a peptide cell-permeabilization sequence, the hydrophobic region (h-region) of the signal peptide of Kaposi fibroblast growth factor (K-FGF). SN50 Peptide inhibits translocation of the NF-κB active complex into the nucleus. | [in vivo]
Treatment with SN50 accelerates the recovery of motor functional outcome from 1st to 4th day. Animals subjected to SN50 pretreatment demonstrate a significant decrease in the visuospatial learning latencies relative to the control group at 7 and 8 days post-TBI. Pretreatment with SN50 results in a significant reduction of NF-κB p65 protein levels from 6 to 48 h post-TBI and TNF-a protein levels from 12 to 48 h post-TBI[1]. | [IC 50]
NF-κB |
|
| Company Name: |
Sigma-Aldrich
|
| Tel: |
021-61415566 800-8193336 |
| Website: |
https://www.sigmaaldrich.cn |
|